发明名称 |
Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepatanoic acid |
摘要 |
Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease. |
申请公布号 |
US9309195(B2) |
申请公布日期 |
2016.04.12 |
申请号 |
US201514716361 |
申请日期 |
2015.05.19 |
申请人 |
Pfizer Inc. |
发明人 |
Krzyzaniak Joseph Francis;Leonard Jason Albert |
分类号 |
C07D207/34;C07D295/037;C07C211/07;C07C215/08;C07C229/26;C07D295/027 |
主分类号 |
C07D207/34 |
代理机构 |
|
代理人 |
Tinney Francis J. |
主权项 |
1. An atorvastatin olamine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKα radiation: 8.5, 9.8, 17.4, 18.6, 20.9, 22.5, and 24.1, or a solid state 19F nuclear magnetic resonance having the following chemical shifts measured in parts per million: −118.7. |
地址 |
New York NY US |